Crescent Biopharma (NASDAQ:CBIO) Stock Moved Down to Sell by Wall Street Zen

Crescent Biopharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Crescent Biopharma to “sell” from “hold.” Other analysts remain more positive overall: MarketBeat lists a “Moderate Buy” consensus and a $33.17 average price target.
  • The company reported a quarterly loss of $0.90 per share, missing the $0.70 loss analysts expected, while revenue of $3.12 million exceeded the $0.62 million consensus estimate.
  • CBIO opened at $13.00, below its 50-day moving average of $14.10 and 200-day average of $15.95; its 12-month trading range is $8.72 to $27.41.
  • Five stocks to consider instead of Crescent Biopharma.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday, Wall Street Zen reports.

CBIO has been the subject of a number of other research reports. HC Wainwright increased their target price on shares of Crescent Biopharma from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Friday, November 13th. Piper Sandler reduced their target price on shares of Crescent Biopharma from $35.00 to $32.00 and set an "overweight" rating for the company in a report on Friday, November 13th. UBS Group reaffirmed a "buy" rating and set a $36.00 price target on shares of Crescent Biopharma in a research report on Monday, October 19th. TD Cowen upgraded Crescent Biopharma to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Crescent Biopharma in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $33.17.

Check Out Our Latest Stock Report on CBIO

Crescent Biopharma Price Performance

CBIO opened at $13.00 on Friday. The business's fifty day simple moving average is $14.10 and its 200-day simple moving average is $15.95. Crescent Biopharma has a 12-month low of $8.72 and a 12-month high of $27.41.

Crescent Biopharma (NASDAQ:CBIO - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.20). The firm had revenue of $3.12 million for the quarter, compared to analysts' expectations of $0.62 million. Equities analysts predict that Crescent Biopharma will post -3.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Crescent Biopharma

In other Crescent Biopharma news, CEO Joshua T. Brumm sold 7,837 shares of the company's stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $16.71, for a total value of $130,956.27. Following the completion of the transaction, the chief executive officer owned 271,765 shares in the company, valued at approximately $4,541,193.15. This represents a 2.80% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Jonathan McNeill sold 3,839 shares of the stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.71, for a total transaction of $64,149.69. Following the sale, the chief operating officer directly owned 134,588 shares in the company, valued at approximately $2,248,965.48. The trade was a 2.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 16,726 shares of company stock valued at $285,501. Company insiders own 24.84% of the company's stock.

Hedge Funds Weigh In On Crescent Biopharma

A number of large investors have recently bought and sold shares of CBIO. Legal & General Group Plc purchased a new position in shares of Crescent Biopharma during the 2nd quarter valued at approximately $38,000. Simplex Trading LLC acquired a new stake in Crescent Biopharma in the 3rd quarter valued at $50,000. ACT Capital Partners L.P. purchased a new stake in Crescent Biopharma in the 3rd quarter worth $168,000. Persistent Asset Partners Ltd purchased a new stake in Crescent Biopharma in the 2nd quarter worth $197,000. Finally, Wellington Management Group LLP purchased a new stake in Crescent Biopharma in the 2nd quarter worth $263,000. Institutional investors and hedge funds own 75.19% of the company's stock.

About Crescent Biopharma

(Get Free Report)

Crescent Biopharma is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on antibody-based treatments, including therapies designed to target tumor cells and support the body's immune response. The company's work is directed toward advancing oncology drug candidates through clinical development. Its pipeline and programs may change as research progresses, and its products are investigational rather than established treatments. Crescent Biopharma is focused on developing its therapies for cancer patients; detailed information about its geographic operations and leadership is not included here.

Recommended Stories

Analyst Recommendations for Crescent Biopharma (NASDAQ:CBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Crescent Biopharma Right Now?

Before you consider Crescent Biopharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.

While Crescent Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines